1. Hankey GJ, Eikelboom JW. Homocysteine and stroke. Curr Opin Neurol 2001;14:95-102.

2. Hankey GJ, Eikelboom JW. Homocysteine levels in patients with stroke: clinical relevance and therapeutic implications. CNS Druigs 2001;15:437-43.

3. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 2006;580:2994-3005.

4. Loscalzo J. Homocysteine and dementias. N Engl J Med 2002;346:466-8.

5. Hooshmand B, Solomon A, Kåreholt I, Leiviskä J, Rusanen M, Ahtiluoto S, Winblad B, Laatikainen T, Soininen H, Kivipelto M. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology 2010;75:1408-14.

6. Sui R, Zhang L. Depression, Parkinson disease, Alzheimer disease. The homocysteine hypothesis. Neurosciences (Riyadh) 2010;15:211-3.

7. Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004;63:886-91.

8. Zoccolella S, Simone IL, Lamberti P, Samarelli V, Tortelli R, Serlenga L, Logroscino G. Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology 2008;70:222-5.

9. Fraguas R Jr, Papakostas GI, Mischoulon D, Bottiglieri T, Alpert J, Fava M. Anger attacks in major depressive disorder and serum levels of homocysteine. Biol Psychiatry 2006;60:270-4.

10. Gariballa S. Extending the homocysteine-induced neurotransmitter deficiency and depression of mood hypothesis to quality of life in older patients. Int J Geriatr Psychiatry 2013;28:878-9.

11. Folstein M, Liu T, Peter I, Buell J, Arsenault L, Scott T, Qiu WW. The homocysteine hypothesis of depression. Am J Psychiatry 2007;164:861-7.

12. Gariballa S. Testing homocysteine-induced neurotransmitter deficiency, and depression of mood hypothesis in clinical practice. Age Ageing 2011;40:702-5.

13. Levine J, Sela BA, Osher Y, Belmaker RH. High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1181-91.

14. Brown AS, Susser ES. Homocysteine and schizophrenia: from prenatal to adult life. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1175-80.

15. Ansari R, Mahta A, Mallack E, Luo JJ. Hyperhomocysteinemia and neurologic disorders: a review. J Clin Neurol 2014;10:281-8.

16. Luo JJ, Sivaraaman K, Nouh A, Dun NJ. Elevated plasma level of homocysteine is an independent risk factor for peripheral neuropathy. Br J Med Med Res 2014;4:161-9.

17. Aminoff MJ. Aminoff's Electrodiagnosis in Clinical Neurology. 6th ed. Philadelphia: Saunders; 2012 .

18. Luo JJ, Bumanlag F, Dun NJ. Electrophysiologic features of peripheral neuropathy in adults with an isolated elevated plasma level of homocysteine. J Neurol Transl Neurosci 2013;2:1027-31.

19. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20:6920-6.

20. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 1997;94:5923-8.

21. Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med 2006;166:1519-24.

22. Ammendola A, Gemini D, Iannaccone S, Argenzio F, Ciccone G, Ammendola E, Serio L, Ugolini G, Bravaccio F. Gender and peripheral neuropathy in chronic alcoholism: a clinical-electroneurographic study. Alcohol Alcohol 2000;35:368-71.

23. Aaberg ML, Burch DM, Hud ZR, Zacharias MP. Gender differences in the onset of diabetic neuropathy. J Diabetes Complications 2008;22:83-7.

24. Mathew PG, Dun EC, Luo JJ. A cyclic pain: the pathophysiology and treatment of menstrual migraine. Obstet Gynecol Surv 2013;68:130-40.

25. Pirart J, Lauvaux JP, Rey W. Blood sugar and diabetic complications. N Engl J Med 1978;298:1149.

26. Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes 1988;37:476-81.

27. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995;122:561-8.

28. Liu XX, Wilson K, Charlton CG. Effects of L-dopa treatment on methylation in mouse brain: implications for the side effects of L-dopa. Life Sci 2000;66:2277-88.

29. Hofmann MA, Kohl B, Zumbach MS, Borcea V, Bierhaus A, Henkels M, Amiral J, Schmidt AM, Fiehn W, Ziegler R, Wahl P, Nawroth PP. Hyperhomocyst (e) inemia and endothelial dysfunction in IDDM. Diabetes Care 1998;21:841-8.

30. Kulkarni K, Richard BC. Lifestyle, homocysteine, and the metabolic syndrome. Metab Syndr Relat Disord 2003;1:141-7.

31. Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. Atherosclerosis 1998;139:197-8.

32. Munshi MN, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996;45:133-5.

33. Kawasaki A, Purvin VA, Burgett RA. Hyperhomocysteinaemia in young patients with non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 1999;83:1287-90.

34. Kim WK, Pae YS. Involvement of N-methyl-d-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture. Neurosci Lett 1996;216:117-20.

35. Outinen PA, Sood SK, Liaw PC, Sarge KD, Maeda N, Hirsh J, Ribau J, Podor TJ, Weitz JI, Austin RC. Characterization of the stress-inducing effects of homocysteine. Biochem J 1998;332:213-21.

36. Huang RF, Huang SM, Lin BS, Wei JS, Liu TZ. Homocysteine thiolactone induces apoptotic DNA damage mediated by increased intracellular hydrogen peroxide and caspase 3 activation in HL-60 cells. Life Sci 2001;68:2799-811.

37. Maler JM, Seifert W, Hüther G, Wiltfang J, Rüther E, Kornhuber J, Bleich S. Homocysteine induces cell death of rat astrocytes in vitro. Neurosci Lett 2003;347:85-8.

38. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003;26:137-46.

39. Smith AD. The worldwide challenge of the dementias: a role for B vitamins and homocysteine? Food Nutr Bull 2008;29:S143-72.

40. Savage DG, Lindenbaum J. 11 Neurological complications of acquired cobalamin deficiency: clinical aspects. Baillieres Clin Haematol 1995;8:657-78.

41. Yi Y, Kang HJ, Shin HY, Kim K. Progressive myelopathy mimicking subacute combined degeneration after intrathecal chemotherapy. J Child Neurol 2014. Epub ahead of print.

42. Luo JJ, Dun NJ. Should homocysteine be a therapeutic target for neurological disorders? Brain Disord Ther 2013;2:e107.

Neuroimmunology and Neuroinflammation
ISSN 2349-6142 (Online) 2347-8659 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: